MTORC1/2 signaling pathway in cancer research

doi:10.3877/cma.j.issn.1674-1366.2018.06.011

Abstract

Abstract:

Mammalian target of rapamycin (mTOR) is a critical effective protein in the downstream of PI3K-Akt pathway. When activated by growth factors, nutrition or energy signals in eukaryotes, mTOR can accelerate the synthesis of protein, which is beneficial to the growth of tumor cells. Thus, mTOR is an important target of cancer treatment. Rapamycin (Sirolimus) and its analogues have specific inhibitory effects on mTOR and are used in clinical treatment of many types of cancer. Due to the high heterogeneity and complexity of tumors, some show resistance to mTOR inhibitors. Therefore, it is of great significance to understand the mechanism of mTOR pathway in tumor proliferation and survival, and to further improve the treatment efficacy.

Key words: Sirolimus, Neoplasms, Therapeutics, Mammals, Mechanistic target of rapamycin complex 1, Mechanistic target of rapamycin complex 2

Shanwei Shi, Baoshan Xu. MTORC1/2 signaling pathway in cancer research[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2018, 12(06): 383-388.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhkqyxyjzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1366.2018.06.011

https://zhkqyxyjzz.cma-cmc.com.cn/EN/Y2018/V12/I06/383

References 66

[1]	Chiang GG, Abraham RT. Determination of the catalytic activities of mTOR and other members of the phosphoinositide-3-kinase-related kinase family [J]. Methods Mol Biol, 2004(281):125-141.
[2]	Zoncu R, Efeyan A, Sabatini DM. mTOR：from growth signal integration to cancer, diabetes and ageing [J]. Nat Rev Mol Cell Biol, 2011, 12(1):21-35.
[3]	Brown MC, Gromeier M. MNK inversely regulates TELO2 vs. DEPTOR to control mTORC1 signaling [J]. Mol Cell Oncol, 2017, 4(3):e1306010.
[4]	Liu P, Gan W, Chin YR, et al. PtdIns（3, 4, 5）P3-Dependent Activation of the mTORC2 Kinase Complex [J]. Cancer Discov, 2015, 5(11):1194-1209.
[5]	Laplante M, Sabatini DM. mTOR signaling in growth control and disease [J]. Cell, 2012, 149(2):274-293.
[6]	Nasr AB, Ponnala D, Sagurthi SR, et al. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions [J]. Bioinformation, 2015, 11(6):307-315.
[7]	Schreiber KH, Ortiz D, Academia EC, et al. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins [J]. Aging Cell, 2015, 14(2):265-273.
[8]	Khan KH, Yap TA, Yan L, et al. Targeting the PI3K-AKT-mTOR signaling network in cancer [J]. Chin J Cancer, 2013, 32(5):253-265.
[9]	Gowans GJ. Regulation and role of the LKB1-AMPK pathway [D]. Dundee：University of Dundee, 2014.
[10]	Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis [J]. Adv Cancer Res, 2009, 102(1):19-65.
[11]	Yuan TL, Cantley LC. PI3K pathway alterations in cancer：variations on a theme [J]. Oncogene, 2008, 27(41):5497-5510.
[12]	Foukas LC, Berenjeno IM, Gray A, et al. Activity of any class IA PI3K isoform can sustain cell proliferation and survival [J]. Proc Natl Acad Sci U S A, 2010, 107(25):11381-11386.
[13]	McGlade CJ, Ellis C, Reedijk M, et al. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors [J]. Mol Cell Biol, 1992, 12(3):991-997.
[14]	Balendran A, Casamayor A, Deak M, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2 [J]. Curr Biol, 1999, 9(8):393-404.
[15]	Leslie NR, Batty IH, Maccario H, et al. Understanding PTEN regulation：PIP2, polarity and protein stability [J]. Oncogene, 2008, 27(41):5464-5476.
[16]	Lin HP, Lin CY, Huo C, et al. Akt3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2[J]. Oncotarget, 2015, 6(29):27097-27112.
[17]	Dibble CC, Elis W, Menon S, et al. TBC1D7 Is a third subunit of the TSC1-TSC2 complex upstream of mTORC1 [J]. Mol Cell, 2012, 47(4):535-546.
[18]	Yoshida S, Hong S, Suzuki T, et al. Redox regulates mammalian target of rapamycin complex 1（mTORC1）activity by modulating the TSC1/TSC2-Rheb GTPase pathway [J]. J Biol Chem, 2011, 286(37):32651-32660.
[19]	Mohan N, Shen Y, Dokmanovic M, et al. VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation [J]. Oncotarget, 2016, 7(32):52239-52254.
[20]	Han D, Li SJ, Zhu YT, et al. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer [J]. Asian Pac J Cancer Prev, 2013, 14(7):4033-4099.
[21]	Mirouse V, Swick LL, Kazgan N, et al. LKB1 and AMPK maintain epithelial cell polarity under energetic stress [J]. J Cell Biol, 2013, 203(2):387-392.
[22]	Hardie DG, Sakamoto K. AMPK：a key sensor of fuel and energy status in skeletal muscle [J]. Physiology（Bethesda）, 2006(21):48-60.
[23]	Green AS, Chapuis N, Lacombe C, et al. LKB1/AMPK/mTOR signaling pathway in hematological malignancies：from metabolism to cancer cell biology [J]. Cell Cycle, 2011, 10(13):2115-2120.
[24]	Wang W, Guan KL. AMP-activated protein kinase and cancer [J]. Acta Physiol（Oxf）, 2009, 196(1):55-63.
[25]	Dodd KM, Yang J, Shen MH, et al. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3 [J]. Oncogene, 2015, 34(17):2239-2250.
[26]	Jevtov I, Zacharogianni M, Oorschot MM, et al. TORC2 mediates the heat stress response in Drosophila by promoting the formation of stress granules [J]. J Cell Sci, 2015, 128(14):2497-2508.
[27]	Iadevaia V, Liu R, Proud CG. mTORC1 signaling controls multiple steps in ribosome biogenesis [J]. Semin Cell Dev Biol, 2014(36):113-120.
[28]	Yuan L, Sheng X, Willson AK, et al. Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway [J]. Endocr Relat Cancer, 2015, 22(4):577-591.
[29]	Vikhreva PN, Shepelev MV, Korobko IV. mTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells [J]. Biochim Biophys Acta, 2014, 1839(1):43-49.
[30]	Csibi A, Lee G, Yoon SO, et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation [J]. Curr Biol, 2014, 24(19):2274-2280.
[31]	Dan HC, Antonia RJ, Baldwin AS. PI3K/Akt promotes feedforward mTORC2 activation through IKKα [J]. Oncotarget, 2016, 7(16):21064-21075.
[32]	Zinzalla V, Stracka D, Oppliger W, et al. Activation of mTORC2 by association with the ribosome [J]. Cell, 2011, 144(5):757.
[33]	Oh WJ, Wu CC, Kim SJ, et al. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide [J]. EMBO J, 2010, 29(23):3939-3951.
[34]	Renna M, Bento CF, Fleming A, et al. IGF-1 receptor antagonism inhibits autophagy [J]. Hum Mol Genet, 2013, 22(22):4528-4544.
[35]	Liu P, Gan W, Inuzuka H, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signaling to suppress tumorigenesis [J]. Nat Cell Biol, 2013, 15(11):1340-1350.
[36]	Masri J, Bernath A, Martin J, et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor [J]. Cancer Res, 2007, 67(24):11712-11720.
[37]	Guertin DA, Sabatini DM. Defining the role of mTOR in cancer [J]. Cancer Cell, 2007, 12(1):9-22.
[38]	Cargnello M, Tcherkezian J, Roux PP. The expanding role of mTOR in cancer cell growth and proliferation [J]. Mutagenesis, 2015, 30(2):169-176.
[39]	Karthik GM, Ma R, Lövrot J, et al. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells [J]. Cancer Lett, 2015, 367(1):76-87.
[40]	Caron A, Richard D, Laplante M. The Roles of mTOR Complexes in Lipid Metabolism [J]. Annu Rev Nutr, 2015(35):321-348.
[41]	Shor B, Gibbons JJ, Abraham RT, et al. Targeting mTOR globally in cancer：thinking beyond rapamycin [J]. Cell Cycle, 2009, 8(23):3831-3837.
[42]	Chatterjee A. Control of cell cycle progression by mTOR [D]. New York：City University of New York, 2015.
[43]	Teo T, Yu M, Yang Y, et al. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells [J]. Cancer Lett, 2015, 357(2):612-623.
[44]	Feng L, Balakir R, Precht P, et al. Bcl-2 regulates chondrocyte morphology and aggrecan gene expression independent of caspase activation and full apoptosis [J]. J Cell Biochem, 2015, 74(4):576-586.
[45]	Zhou FF, Yan M, Guo GF, et al. Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells [J]. Med Oncol, 2011, 28(4):1302-1307.
[46]	Harada H, Andersen JS, Mann M, et al. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD [J]. Proc Natl Acad Sci U S A, 2001, 98(17):9666-9670.
[47]	Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation [J]. Cell, 2005, 120(6):747-759.
[48]	Kenific CM, Debnath J. Cellular and metabolic functions for autophagy in cancer cells [J]. Trends Cell Biol, 2015, 25(1):37-45.
[49]	Jiang X, Overholtzer M, Thompson CB. Autophagy in cellular metabolism and cancer [J]. J Clin Invest, 2015, 125(1):47-54.
[50]	Chan EY. mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex [J]. Sci Signal, 2009, 2(84):pe51.
[51]	Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy [J]. FEBS Lett, 2010, 584(7):1287-1295.
[52]	Easton JB, Houghton PJ. mTOR and cancer therapy [J]. Oncogene, 2006, 25(48):6436-6446.
[53]	Ortolani S, Ciccarese C, Cingarlini S, et al. Suppression of mTOR pathway in solid tumors：lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives [J]. Future Oncol, 2015, 11(12):1809-1828.
[54]	Sapienza PJ, Mauldin RV, Lee AL. Multi-timescale dynamics study of FKBP12 along the rapamycin-mTOR binding coordinate [J]. J Mol Biol, 2011, 405(2):378-394.
[55]	O'reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt [J]. Cancer Res, 2006, 66(3):1500-1508.
[56]	Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway：the second generation of inhibitors [J]. Mol Cancer Ther, 2011, 10(3):395-403.
[57]	Neil J, Shannon C, Mohan A, et al. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma [J]. International Journal of Oncology, 2016, 48(3):1045-1052.
[58]	Ma BB, Lui VW, Hui CW, et al. Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models [J]. Cancer Lett, 2014, 343(1):24-32.
[59]	Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies [J]. Blood, 2012, 119(2):476-487.
[60]	Wu S, Wang S, Zheng S, et al. MSK1-mediated β-catenin phosphorylation confers resistance to PI3K/mTOR inhibitors in glioblastoma[J]. Mol Cancer Ther, 2016, 15(7):1656-1668.
[61]	Elkabets M, Pazarentzos E, Juric D, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas [J]. Cancer Cell, 2015, 27(4):533-546.
[62]	Li T, Yang Y, Li X, et al. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells [J]. Mol Cell Biochem, 2012, 361(1-2):19-29.
[63]	Odaka Y, Xu B, Luo Y, et al. Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells [J]. Carcinogenesis, 2014, 35(1):192-200.
[64]	Zhou H, Shang C, Wang M, et al. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK [J]. Biochem Pharmacol, 2016(116):39-50.
[65]	Chen W, Luo Y, Liu L, et al. Cryptotanshinone inhibits cancer cell proliferation by suppressing mTOR-mediated cyclin D1 expression and Rb phosphorylation [J]. Cancer Prev Res（Phila）, 2010, 3(8):1015-1025.
[66]	Beevers CS, Li F, Liu L, et al. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells [J]. Int J Cancer, 2006, 119(4):757-764.

Please choose a citation manager

Content to export